A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Neoplasms
- Breast Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- June 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- GSK Investigational Site · Encinitas, CA
- GSK Investigational Site · Los Angeles, CA
Georgia · 1
- GSK Investigational Site · Atlanta, GA
Illinois · 1
- GSK Investigational Site · Harvey, IL
Massachusetts · 1
- GSK Investigational Site · Boston, MA
Michigan · 1
- GSK Investigational Site · Grand Rapids, MI
New Jersey · 1
- GSK Investigational Site · Morristown, NJ
New York · 1
- GSK Investigational Site · Lake Success, NY
North Carolina · 1
- GSK Investigational Site · Charlotte, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.